Patents Assigned to TCM Biotech International CORP.
  • Pharmaceutical composition for prevention of recurrent urinary tract infection
    Patent number: 11147832
    Abstract: The present disclosure provides a use of pentosan polysulfate sodium (PPS) in the manufacture of a medicament for the prevention of recurrent urinary tract infection (rUTI) in a human subject, comprising a therapeutically effective dosage for oral administration of PPS, wherein the therapeutically effective dosage for oral administration of PPS is 5-1 mg/kg/day.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: October 19, 2021
    Assignee: TCM BIOTECH INTERNATIONAL CORP.
    Inventors: Ya-Chun Wang, Yu-Ching Chang, Hsiao Tien Ma, Jen-Yau Chen, Yuan-Ju Lee, En Meng, Shang-Jen Chang
  • Pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease
    Patent number: 8858954
    Abstract: The present invention provides a pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease, comprising 50 to 90% by weight of Cordyceps sinensis mycelium powder, and 10 to 50% by weight of condensed astragalus powder.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: October 14, 2014
    Assignee: TCM Biotech International Corp.
    Inventors: Huan Ching Hsu, Ya Chun Wang
  • Methods for making and compositions comprising fermentation products of cordyceps sinensis
    Patent number: 8722056
    Abstract: The present invention relates to novel and non-obvious methods and media for preparing fermentation products of Cordyceps sinensis. The present invention also relates to novel and non-obvious compositions comprising fermentation products of Cordyceps sinensis produced by the methods of the invention or obtained from other sources. The present invention also relates to novel and non-obvious methods of treating patients by administering the compositions of the invention. In one embodiment, the Cordyceps sinensis mycelia is Paecilomyces hepiali mycelia. In another embodiment the compositions of the invention are used to treat patients infected with hepatitis C.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: May 13, 2014
    Assignee: TCM Biotech International Corp.
    Inventors: Ya-Chun Wang, Wang-Sheng Ko, Chih-Cheng Chang
  • Pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease
    Patent number: 8658181
    Abstract: The present invention provides a pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease, comprising 50 to 90% by weight of Cordyceps sinensis mycelium powder, and 10 to 50% by weight of condensed astragalus powder.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: February 25, 2014
    Assignee: TCM Biotech International Corp.
    Inventors: Huan Ching Hsu, Ya Chun Wang
  • Anti-inflammatory effects of the partially purified extract of radix stephaniae tetrandrae
    Publication number: 20040105907
    Abstract: This invention relates to inflammatory responses in isolated peripheral human neutrophils that studied in the presence or absence of specially processed Radix Stephaniae tetrandrae (SPRST). We conclude that SPRST exerts anti-inflammatory effects by interfering with reactive oxygen species (ROS) production and calcium (Ca2+) influx through G-protein modulation to prevent Mac-1 up-regulation and firm adhesion by neutrophils during activation.Thns, SPRST may be clinical beneficial in the prevention of cardiovascular disease, or other diseases related to over activation of neutrophil.
    Type: Application
    Filed: August 5, 2003
    Publication date: June 3, 2004
    Applicant: TCM Biotech International CORP.
    Inventors: Chieh-Fu Chen, Cheng-Jen Chou, Yuh-Chiang Shen